Polysaccharide surface modified Fe3O4 nanoparticles for camptothecin loading and release.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 19286431.
- Also identified by DOI 10.1016/j.actbio.2008.10.022.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fe(3)O(4) nanoparticles were stabilized using different functional polysaccharides, such as chitosan (CS), O-carboxymethylchitosan (OCMCS) and (N-succinyl-O-carboxymethylchitosan (NSOCMCS) to improve their bioactivity. The release profile and the in vitro cancer cell inhibition activity of camptothecin (CPT) loaded polysaccharide modified Fe(3)O(4) nanoparticles were systematically studies. The particle size and size distribution of CPT-loaded polysaccharide modified Fe(3)O(4) nanoparticles were found to be strongly dependent on polysaccharide character. Such polysaccharide character could also affect CPT adsorption efficiency, CPT release behavior and bovine serum albumin (BSA) unspecific binding capacity. After 24 h incubation of 7721 cancer cells with CPT-loaded polysaccharide modified Fe(3)O(4) nanoparticles, significant changes in cell morphology could be discernible from phase contrast microscopy. Cytotoxicity assay showed these polysaccharide modified Fe(3)O(4) nanoparticles did not exhibit noteworthy cytotoxicity against 7721, however, the in vitro inhibition rate of CPT-loaded polysaccharide modified Fe(3)O(4) nanoparticles against 7721 liver cancer cell increased significantly in comparison with that of CPT-free drug.
Medical subject headings
- Camptothecin
- Drug Carriers
- Drug Delivery Systems
- Ferric Compounds
- Nanoparticles
- Polysaccharides